MIRA Pharmaceuticals (MIRA) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuphoria Therapeutics (NEUP) has outperformed MIRA Pharmaceuticals (MIRA) over the past year, losing 47.3% versus a loss of 79.1%. Neuphoria Therapeutics is the larger company by market cap ($12.7 million vs $12.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIRA | NEUP |
|---|---|---|
| Share price | $0.291 | $2.35 |
| Market cap | $12.23M | $12.72M |
| 1-day change | -20.84% | +1.29% |
| YTD return | -80.73% | -39.43% |
| 1-year return | -79.06% | -47.31% |
| P/E ratio (TTM) | 29.10 | — |
| EPS (TTM) | $0.01 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.17M |
| Revenue growth (YoY) | — | -92.50% |
| Net income (latest FY) | $-10.44M | $-13.45M |
| Operating margin | — | -1401.09% |
| Net margin | — | -1145.66% |
| 52-week high | $1.69 | $5.53 |
| 52-week low | $0.255 | $2.26 |
| Distance from 52-week high | -82.78% | -57.50% |
| Analyst consensus | none | none |
| Avg. price target upside | +1102.75% | — |
| Average volume | 622.02K | 26.53K |
| Shares outstanding | 42.02M | 5.41M |
| Employees | — | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEUP has outperformed MIRA by 31.8 percentage points over the past year.
About MIRA Pharmaceuticals
MIRA stock →MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
Health Care · Biotechnology: Pharmaceutical Preparations
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
MIRA vs NEUP FAQ
Which is bigger, MIRA Pharmaceuticals or Neuphoria Therapeutics?
Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $12.72M compared with $12.23M for MIRA Pharmaceuticals (MIRA).
Which stock has performed better over the past year, MIRA or NEUP?
NEUP returned -47.31% over the past 12 months, compared with -79.06% for MIRA (price return, excluding dividends). Past performance does not predict future results.
Are MIRA Pharmaceuticals and Neuphoria Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.